AI-Designed cancer vaccine enters human testing for colorectal cancer
NCT ID NCT07328087
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a personalized vaccine called COLONYVAQ-CRC, designed using AI and quantum physics, for patients with stage III colorectal cancer that has been surgically removed. The vaccine is given alongside standard chemotherapy and an immunotherapy drug (nivolumab). The main goal is to check safety and side effects in 12 to 50 participants. Researchers will also look at immune responses and whether the vaccine helps keep cancer from coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized neoantigen peptide vaccine (COLONYVAQ-CRC)
What this could lead to
If successful, this could lead to a new personalized vaccine approach to help prevent colorectal cancer from returning after surgery.
What could go wrong
This is a very early, small trial (12-50 people) focused on safety. The vaccine is custom-made for each patient, which is complex and may not work for everyone. Side effects from the combination treatment are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Biogenea Pharmaeuticals Ltd
RECRUITINGThessaloniki, 54627, Greece